IP Library › Granted Patent US 9,447,087
Granted Patent B2
US 9,447,087 · App. 14/346,400 · Granted Sep 20, 2016

Galactokinase inhibitors for the treatment and prevention of associated diseases and disorders

Inventors: Matthew B. Boxer (New Market, MD); Martin J. Walsh (Carmel, IN); Li Liu (Germantown, MD); Cordelle D. Tanega (Virginia Beach, VA); Min Shen (Boyds, MD); Kent Lai (Salt Lake City, UT); Manshu Tang (Salt Lake City, UT); Douglas S. Auld (Beverly, MA)
Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
C07D417/14A61K31/506C07D403/12C07D413/12C07D413/14C07D491/107C07D493/10C07D495/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,447,087
App. No.
14/346,400
Granted
Sep 20, 2016
Kind
B2
Abstract

Disclosed are inhibitors of human galactokinase of formula (1) that are useful in treating or preventing a galactokinase mediated disease or disorder, e.g., galactosemia. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one inhibitor of the invention, and a method of treating or preventing such disease or disorder in a mammal. Formula (I).

Claims (14)

1. A compound selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

3. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

4. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

5. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

6. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

7. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

8. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

9. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

10. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

11. The compound or salt of claim 1 , wherein the compound is:

12. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

13. The compound or salt of claim 1 , wherein the compound is selected from the group consisting of:

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 7, 2014
From: BOXER, MATTHEW B.; WALSH, MARTIN J.; LIU, LI; TANEGA, CORDELLE D.; SHEN, MIN; LAI, KENT; TANG, MANSHU; AULD, DOUGLAS S.
To: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES; UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 032838/0573 →
Continuity (1)
Related Publication 20140288100A1 · Sep 25, 2014